Correlation Between mTOR Pathway and Clinical Outcomes in Patients with Well-Differentiated Neuroendocrine Tumors Treated with Everolimus Abstract #513

Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.
Aim(s): To determine the expression of some factors of the pathway of p-mTOR in patients treated with Everolimus and to evaluate the possible correlations with the clinical outcomes: response rate (RR), time to progression (TTP), and overall survival (OS).
Materials and methods: We reviewed the clinical records of patients with histological diagnosis of progressive advanced unresectable NETs. The tumors were defined according to WHO 2010 classification. The tissue tumor samples were centrally (IEO) analysed to detect subtype 2 somatostatin receptor, phospho-AKT, phospho-mTOR, phospho-4E-BP1, phospho-p70-S6 kinase, PTEN, mutations of PI3K gene.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Francesca Spada
Keywords: mTOR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#945 Interference of Nutrient/Oxygen Availability with mTOR Activation and Inhibition in Lung Carcinoids: A Tissue and Cellular Study
Introduction: MTOR is capable of coupling cellular nutrient sensing to metabolic homeostasis. However, little is known of the interactions between cancerā€specific metabolic pathways and profiles of responsiveness to mTOR inhibition in neuroendocrine tumors.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Prof Marco Volante
Authors: Rapa I, Giorcelli J, Votta A, Marino G, ...
#364 Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).
Conference:
Category: Basic
Presenting Author: MD FRANCESCA SPADA
#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus
Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Chiara Alessandra Cella
Authors: Cella C A, Barberis M, Spad F, Pisa E, ...
Keywords: Everolimus, MET, RET
#919 Effect of Combined Treatment with mTOR Inhibitors (mTORi) and Dopamine Agonists on Cell Proliferation in a Human Typical Lung Carcinoid Cell Line
Introduction: The mTOR pathway and dopamine receptors are potential targets for treatment of neuroendocrine tumors (NET).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Maddalena Sarnataro
Keywords: mTOR, dopamine
#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H, ...